It has been proven in mouse cancer models that simultaneous blocking of LAG-3 and PD-1 co-expressed on CD4+ and CD8+ TILs can synergistically improve anti-tumor CD8+ T cell responses. The gene discussed is CD8A; the disease is cancer.